Get started

Niftypharma

SYNCOMF FOR 3-6 MONTHSFor 3-6 Months Fundamentally, > Revenue Growth over 60% Quarterly > Net Income Growth over 70% Quarterly > EPS over 40% Yearly Technically, > Trading at the point of historically tested demand zone. > Rising relative strength. > Market Profile also suggesting an upmove. > Current levels suggests buyer's entry with volumes. Risk to Reward is 1:2.5 or more Profit Targets: 22-28, Can book some profits at first target and then trail SL further. Stop Loss: Below the current support, 19
NSE:SYNCOMFLong
by madhubansal
LAURUS LAB By KRS ChartsDate: 21st Aug 2024 Time: 9:32 AM Why Laurus Lab? 1. Correction Wave was finished with 5th wave low in Mar 2023, after that it gradually moving up and made upside channeling. 2. Currently price is sustaining above 100 EMA and likely to reversed from that too. 🤞 3. why I'm keen to post L Lab is because along with both above points its likely to close and try to be making Morning Star at bottom in 1W TF. Lauras Lab is at better price at this level with Future Targets of 525 and 605. SL would be flexible Weekly Closing Below 100EMA Once Morning Star Closing will confirm at end of this week this trade will Activated 🎇
NSE:LAURUSLABSLong
by KRSCharts
2
Aurobindo Pharma: Breakout with a Long Opportunity?Aurobindo Pharma is showing signs of a trend reversal on the daily chart. The stock has broken above a descending trendline, supported by strong volumes, signaling a potential bullish move. Key Levels to Watch: Support: ₹1,253 Resistance: ₹1,346 and ₹1,407 Long Opportunity: If the stock sustains above ₹1,300, it offers a good long opportunity with a target of ₹1,407 in the short term. A close above ₹1,407 could open doors to further upside. Traders can consider ₹1,253 as a stop-loss for a risk-managed entry. A decisive move above ₹1,346 will confirm bullish momentum, making this a promising setup for long-term gains.
NSE:AUROPHARMALong
by ayusharya_001
Lupin Ltd: Technical Analysis - December 2024Lupin Ltd (NSE: LUPIN) has displayed an impressive uptrend throughout 2024, supported by a strong ascending trendline (yellow). The stock has experienced healthy corrections along the way, forming a well-defined channel (blue) during its recent consolidation phase. Let’s break it down: Key Observations: Uptrend Continuation: The broader trend remains bullish, with the stock bouncing off the lower boundary of the channel and showing signs of a potential breakout above the resistance. Channel Pattern: A descending channel formation suggests a corrective move within the larger uptrend. The breakout towards the upper end of this channel indicates renewed buying interest. Support & Resistance Levels: Key Support: ₹1,697.50 (red horizontal line), which aligns with a previous demand zone. Immediate Resistance: ₹2,200 - ₹2,250, marking the channel breakout zone. Outlook: A sustained move above ₹2,200 could trigger a new leg of the rally, targeting ₹2,400 and beyond. On the downside, ₹1,900 and ₹1,697.50 will act as crucial supports in case of a pullback. Trading Strategy: Bullish Bias: Buy on dips near ₹2,100-₹2,150 with a stop-loss at ₹1,900. Breakout Play: Enter on a decisive close above ₹2,200 for potential upside. This technical setup provides a promising outlook for Lupin, making it a stock to watch in early 2025.
NSE:LUPINLong
by ayusharya_001
IPCA LABS - Shorts below 1550 you may think of buying a put option or selling futures if IPCA labs closes below 1550 levels and then you can thank me later by boosting, liking and sharing the post. One of the first modern pharma factory of yesteryears was commissioned by Ipca at Mumbai in 1969. The company was originally promoted by a group of medical professionals and businessmen and was incorporated as 'The Indian Pharmaceutical Combine Association Limited. ' in October 1949. Thank you.
NSE:IPCALABShort
by piyushbafna000
Torrent PharmaAll important points are marked. 𝐃𝐢𝐬𝐜𝐥𝐚𝐢𝐦𝐞𝐫: 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐢𝐧 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐢𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐫𝐞 𝐬𝐮𝐛𝐣𝐞𝐜𝐭 𝐭𝐨 𝐦𝐚𝐫𝐤𝐞𝐭 𝐫𝐢𝐬𝐤𝐬, 𝐫𝐞𝐚𝐝 𝐚𝐥𝐥 𝐭𝐡𝐞 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐝𝐨𝐜𝐮𝐦𝐞𝐧𝐭𝐬 𝐜𝐚𝐫𝐞𝐟𝐮𝐥𝐥𝐲 𝐛𝐞𝐟𝐨𝐫𝐞 𝐢𝐧𝐯𝐞𝐬𝐭𝐢𝐧𝐠. 𝐒𝐭𝐨𝐜𝐤𝐬 𝐬𝐮𝐠𝐠𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐠𝐫𝐨𝐮𝐩 𝐚𝐫𝐞 𝐟𝐨𝐫 𝐞𝐝𝐮𝐜𝐚𝐭𝐢𝐨𝐧 𝐩𝐮𝐫𝐩𝐨𝐬𝐞. 𝐖𝐞 𝐝𝐨𝐧𝐭 𝐦𝐚𝐤𝐞 𝐚𝐧𝐲 𝐩𝐫𝐨𝐟𝐢𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐢𝐬 𝐫𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐚𝐭𝐢𝐨𝐧𝐬 𝐞𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠 𝐬𝐡𝐚𝐫𝐞𝐝 𝐡𝐞𝐫𝐞 𝐚𝐫𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐞𝐥𝐲 𝐨𝐟 𝐟𝐫𝐞𝐞 𝐨𝐟 𝐜𝐨𝐬𝐭.
NSE:TORNTPHARMLong
by sreekumars
GRANULES INDIA LTDBuy above 595 All important points are marked. 𝐃𝐢𝐬𝐜𝐥𝐚𝐢𝐦𝐞𝐫: 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐢𝐧 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐢𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐫𝐞 𝐬𝐮𝐛𝐣𝐞𝐜𝐭 𝐭𝐨 𝐦𝐚𝐫𝐤𝐞𝐭 𝐫𝐢𝐬𝐤𝐬, 𝐫𝐞𝐚𝐝 𝐚𝐥𝐥 𝐭𝐡𝐞 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐝𝐨𝐜𝐮𝐦𝐞𝐧𝐭𝐬 𝐜𝐚𝐫𝐞𝐟𝐮𝐥𝐥𝐲 𝐛𝐞𝐟𝐨𝐫𝐞 𝐢𝐧𝐯𝐞𝐬𝐭𝐢𝐧𝐠. 𝐒𝐭𝐨𝐜𝐤𝐬 𝐬𝐮𝐠𝐠𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐠𝐫𝐨𝐮𝐩 𝐚𝐫𝐞 𝐟𝐨𝐫 𝐞𝐝𝐮𝐜𝐚𝐭𝐢𝐨𝐧 𝐩𝐮𝐫𝐩𝐨𝐬𝐞. 𝐖𝐞 𝐝𝐨𝐧𝐭 𝐦𝐚𝐤𝐞 𝐚𝐧𝐲 𝐩𝐫𝐨𝐟𝐢𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐢𝐬 𝐫𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐚𝐭𝐢𝐨𝐧𝐬 𝐞𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠 𝐬𝐡𝐚𝐫𝐞𝐝 𝐡𝐞𝐫𝐞 𝐚𝐫𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐞𝐥𝐲 𝐨𝐟 𝐟𝐫𝐞𝐞 𝐨𝐟 𝐜𝐨𝐬𝐭.
NSE:GRANULESLong
by sreekumars
AJANTA PHARMA LTDBuy Ajanta above: 3351 only. All important points are marked. 𝐃𝐢𝐬𝐜𝐥𝐚𝐢𝐦𝐞𝐫: 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐢𝐧 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐢𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐫𝐞 𝐬𝐮𝐛𝐣𝐞𝐜𝐭 𝐭𝐨 𝐦𝐚𝐫𝐤𝐞𝐭 𝐫𝐢𝐬𝐤𝐬, 𝐫𝐞𝐚𝐝 𝐚𝐥𝐥 𝐭𝐡𝐞 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐝𝐨𝐜𝐮𝐦𝐞𝐧𝐭𝐬 𝐜𝐚𝐫𝐞𝐟𝐮𝐥𝐥𝐲 𝐛𝐞𝐟𝐨𝐫𝐞 𝐢𝐧𝐯𝐞𝐬𝐭𝐢𝐧𝐠. 𝐒𝐭𝐨𝐜𝐤𝐬 𝐬𝐮𝐠𝐠𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐠𝐫𝐨𝐮𝐩 𝐚𝐫𝐞 𝐟𝐨𝐫 𝐞𝐝𝐮𝐜𝐚𝐭𝐢𝐨𝐧 𝐩𝐮𝐫𝐩𝐨𝐬𝐞. 𝐖𝐞 𝐝𝐨𝐧𝐭 𝐦𝐚𝐤𝐞 𝐚𝐧𝐲 𝐩𝐫𝐨𝐟𝐢𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐢𝐬 𝐫𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐚𝐭𝐢𝐨𝐧𝐬 𝐞𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠 𝐬𝐡𝐚𝐫𝐞𝐝 𝐡𝐞𝐫𝐞 𝐚𝐫𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐞𝐥𝐲 𝐨𝐟 𝐟𝐫𝐞𝐞 𝐨𝐟 𝐜𝐨𝐬𝐭.
NSE:AJANTPHARMLong
by sreekumars
Nifty Pharma: Displaying Strength at the Summit(1) The price has been consistently trending upwards over the past year. (2) Following the breakout of the Pole & Flag pattern, the price surged sharply. (3) Subsequently, the price entered an accumulation phase and began consolidating within a Box pattern, which is a positive sign after a strong rally. (4) After 3 months of consolidation, the price finally broke out and started moving upwards. (5) The price is currently at its all-time high and appears poised to continue rising.
NSE:CNXPHARMA
by GoodluckCapital
4
NIFTY PHARMA Sector Analysis - 10th July, 2024NIFTY PHARMA Sector Analysis (1W TF) - 10th July, 2024 - After the breakout of the box consolidation in beginning of June, 2024 - The entire set of stocks in this sector has been showing continuous strength - Looks like there is a little more steam for the sector till it hits a pause at the resistance - Even with todays volatility the stocks showed some good pullbacks towards the end of the day Stocks in Focus: - Will be keeping a close eye on SYNGENE & GLAND (on a weekly time frame) - Going to wait it out for another day for the charts to form to give a sense of clarity Sector Stocks that have shown continuous strength from beginning of 2024: - Auropharma, Biocon, Divislab, Glenmark etc Sector Stocks that have show reversals since June, 2024: - AbbotIndia, Alkem , Cipla, DrReddy, Gland etc * Disclaimer
NSE:CNXPHARMALong
by TradeRyteStockz
Wockpharma: DTL BO?-if Nifty Pharma breakout from long Parallel Channel (PC), Wockpharma can be one of pharma companies to perform, as it also forming long base and, Long Base = Long Breakout . -DTL BO anticipation (Down Trendline Breakout), tested 4 times but didnt fall with volumes. -Clearly, Green vol > Red vol -VCP pattern (15W-22/6-3Ts) -Earnings due on 28th May Setup is solid lets see how it work out. Cheat entry (Cheat entry are basically early entry in anticipation of BO) can be around 564ish level BO if day starts with Strong Start (gap up without or barely touching previous day low) But one should wait for confirmation, if it breakout good then it can be confirmation for other stocks too as there are and always will be many opportunities in the market, only one have to seek.
NSE:WOCKPHARMALong
by takmanish007